NCT00054977 - Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

April 30, 2005

Study Completion Date

September 30, 2006

Conditions

Colorectal CancerLung CancerBreast CancerHead and Neck CancerProstate Cancer

Interventions

DRUG

GM-CT-01

IV infusion over 30 minutes of 6 Dosages escalated from 30 to 280 mg/m2, given for 4 consecutive days in a 28 days cycle.

DRUG

5-fluorouracil

IV infusion over 30 minutes at Dosage of 500 mg/m2, given in-combination with GM-CT-01, for 4 consecutive days in a 28 days cycle.

Trial Locations (4)

Florida Oncology Associates, Jacksonville

University of Michigan Comprehensive Cancer Center, Ann Arbor

Ochsner Cancer Institute, New Orleans

Dartmouth-Hitchcock Medical Center, Lebanon